National Bank Direct Brokerage
- Commission-free trading
- Several account types available
- Access to array of research tools
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Sorrento Therape is a biotechnology & medical research business based in the US. Sorrento Therape stocks (SRNE.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $0.3322 – the same closing value as a week prior. Sorrento Therape employs 799 staff and has a trailing 12-month revenue of around $60.3 million.
National Bank Direct Brokerage
CIBC Investor's Edge
|Latest market close||$0.33|
|52-week range||$0.16 - $3.09|
|50-day moving average||$0.77|
|200-day moving average||$1.55|
|Wall St. target price||$13.00|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$-1.53|
Note: The dollar amounts in the table below are in Canadian dollars.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Historical closes compared with the close of $0.3322 from 2023-04-26
|1 week (2023-05-16)||N/A|
|1 month (2023-04-26)||0.3322|
|3 months (2023-02-27)||18.60%|
|6 months (2022-11-25)||-75.39%|
|1 year (2022-05-23)||-78.97%|
|2 years (2021-05-27)||-95.71%|
|3 years (2020-05-27)||5.17|
|5 years (2018-05-25)||7.85|
|Revenue TTM||$60.3 million|
|Gross profit TTM||$-167,049,000|
|Return on assets TTM||-36.87%|
|Return on equity TTM||-378.92%|
|Market capitalisation||$168.4 million|
TTM: trailing 12 months
We're not expecting Sorrento Therape to pay a dividend over the next 12 months.
Sorrento Therape's shares were split on a 1:25 basis on 1 August 2013. So if you had owned 25 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Sorrento Therape shares – just the quantity. However, indirectly, the new 2400% higher share price could have impacted the market appetite for Sorrento Therape shares which in turn could have impacted Sorrento Therape's share price.
Over the last 12 months, Sorrento Therape's shares have ranged in value from as little as $0.161 up to $3.09. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Sorrento Therape's is 1.9435. This would suggest that Sorrento Therape's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Sorrento Therapeutics, Inc. , a clinical stage and commercial biopharmaceutical company, develops therapies for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugate, as well as bispecific antibody approach; and Sofusa, a drug delivery technology that deliver biologic directly into the lymphatic system. Its clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft versus host disease. The company develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis knee pain treatment; and ZTlido, a lidocaine delivery system for the treatment of postherpetic neuralgia. It engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain condition; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation for the treatment of fibromyalgia.
Your guide to how ETFs work and whether this type of investment is right for you.Read more…
The best stock trading app for beginners is easy to use and offers free trades.Read more…
Learning how to read stock charts and recognize chart patterns can unlock your success as a trader.Read more…
We show you the best prepaid credit cards in Canada, whether you’re looking for a prepaid card with no fees, cash back rewards, or travel perks, or more.
This guide provides step-by-step instructions on how to buy Sui, lists some exchanges where you can get it and provides daily price data on (SUI).
Compare apps like Nyble in Canada to access emergency funding.
Your guide to buying and financing a car in Canada with RightRide.
Your guide to bad credit car loans in BC and how to find the right financing for your needs.
Compare six ways to finance a camera in Canada, including options for good and bad credit.
This guide provides step-by-step instructions on how to buy Pepe, lists some exchanges where you can get it and provides daily price data on (PEPE).
Compare lenders to find the best personal loan in Saskatchewan for your needs.
Compare interest rates and eligibility requirements of bad credit loans in Winnipeg.
Teaching teenagers how to budget can be a tricky task. 7 experts give their best tips on how to budget for teenagers.
You must be logged in to post a comment.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.